Henlius' Serplulimab (anti-PD-1 mAb) Granted Breakthrough Therapy Designation by China NMPA for Neo-/Adjuvant Treatment for Gastric Cancer
The first CDE-designated Breakthrough Therapy for perioperative gastric cancer, promising accelerated patient access. The world's first gastric cancer perioperative regimen replacing chemotherapy with immunotherapy alone in the adjuvant setting has...
XCMG Deepens South America Ties with Localization Push, New Hubs, and Sustainable Mining Partnerships
POUSO ALEGRE, Brazil, Nov. 4, 2025 /PRNewswire/ -- Yang Dongsheng, Chairman of XCMG Machinery, met Brazilian President Lula at the Presidential Palace, with the vice president and chief of staff present. Lula praised XCMG's decade-plus...
China, United States can achieve mutual success, shared prosperity
BEIJING, Oct. 31, 2025 /PRNewswire/ -- A report from People's Daily: On Oct. 30, Chinese President Xi Jinping met with his U.S. counterpart Donald Trump in Busan, South Korea. The two heads of state held in-depth discussions on strategic and...
Global Times: Xi says ready to work with Trump to build solid foundation for bilateral ties
BEIJING, Oct. 31, 2025 /PRNewswire/ -- Chinese President Xi Jinping met on Thursday with US President Donald Trump to exchange views on bilateral relations and issues of mutual interest in Busan, South Korea, the Xinhua News Agency reported....
LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE
Results presented at the 17th World Stroke Congress (WSC 2025) LT3001(Odatroltide)-202 phase 2b study met primary endpoint. No symptomatic intracranial hemorrhage occurred. Data suggest that LT3001 has the potential to provide significant clinical...
Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3
The proportion of participants achieving HbA1c < 7.0% and a ≥10% reduction in body weight from baseline was 48.0% in the mazdutide group and 21.0% in the semaglutide group DREAMS-3 is the world's first Phase 3 clinical trial of a GCG/GLP-1 dual...
HARMONi-6 dаta: mPFS 11.14 Months (HR=0.6, P<0.0001) Simultaneously Released at ESMO and in The Lancet
Ivonescimab plus chemotherapy demonstrated a median PFS of 11.14 months, PFS HR=0.60, P < 0.0001. The absolute difference in median PFS between the two groups was 4.24 months (ΔPFS = 4.24 months), indicating significantly prolonged...
Global Times: Xi meets Singaporean PM, calling for boosting China-Singapore cooperation
BEIJING, June 25, 2025 /PRNewswire/ -- Chinese President Xi Jinping met with Singaporean Prime Minister Lawrence Wong in Beijing on Tuesday, the Xinhua News Agency reported. Xi congratulated Wong on his second term in office. Noting that this year...
EPG's Renjun Wan Engages in Digital Infrastructure Talks at 2025 ASEAN-China-GCC Summit, Strengthening Cross-Regional Partnerships
KUALA LUMPUR, Malaysia, June 12, 2025 /PRNewswire/ -- On May 27-28, 2025, the inaugural ASEAN-China-GCC Summit and Economic Forum 2025 took place in Kuala Lumpur, Malaysia. EPG ("EPG"), a leading manufacturing company specializing in prefabricated...
Global Times: Xi hails China-LAC cooperation in meetings with Colombian, Chilean presidents
BEIJING, May 15, 2025 /PRNewswire/ -- Chinese President Xi Jinping met respectively with Colombian President Gustavo Petro and Chilean President Gabriel Boric on Wednesday, who are in Beijing for the fourth ministerial meeting of the China-CELAC...